An overview of the toxicities of checkpoint inhibitors in older patients with cancer.
J Geriatr Oncol
; 9(5): 451-458, 2018 09.
Article
en En
| MEDLINE
| ID: mdl-29567089
ABSTRACT
Checkpoint inhibitors offer an exciting new option for treatment of a wide variety of cancers. By binding to surface receptors or their associated ligands on T cells, this class of drugs enhances immune activation and response to cancer cells. In available studies, the drugs are well tolerated, although toxicity involving skin, gastrointestinal tract, liver, lungs, and endocrine organs has been observed. Unfortunately, few studies to date have included patients older than 70â¯years of age. Since aging has been linked to changes in immune function, there are theoretical concerns that this patient population might experience a different profile of adverse events. This article reviews the tolerability of checkpoint inhibitors in older patients with cancer in clinical practice.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Antineoplásicos Inmunológicos
/
Anticuerpos Monoclonales
/
Neoplasias
Límite:
Aged
/
Aged80
/
Humans
Idioma:
En
Revista:
J Geriatr Oncol
Año:
2018
Tipo del documento:
Article